Roche signs pharmacogenomics pact with Lilly
This article was originally published in Clinica
Executive Summary
Roche Diagnostics - under its business unit Roche Molecular Diagnostics - is collaborating with Eli Lilly to develop pharmacogenomics tests that may identify which patients will benefit most from certain cancer drugs. The Basel, Switzerland firm said that the agreement will initially focus on identifying biomarkers thought to influence patients' survival response rates to Lilly's anti-cancer therapies, pemetrexed (Alimta) and gemcitabine (Gemzar). Roche Molecular Diagnostics will develop any resulting companion diagnostic. Both companies will work with genetic profiling company Response Genetics, based in Los Angeles, California.
You may also be interested in...
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.